Unfortunately, thus far, there is no evidence for the direct involvement of amplification or overexpression of RTK in ER+ disease, a circumstance explaining why no RTKi has been approved yet; (4) RET has emerged as driving oncogenesis not only in thyroid tumors but also in lung cancers as well as in other epithelial tumors (e.g., ERα+ BC)[79]. This evidence concerns the gene ESR1 and thyroid tumor.